Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
November 26, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a...
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
November 25, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology - - Findings Support...
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
November 13, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
- CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to...
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
November 12, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
October 31, 2024 16:15 ET
|
Cognition Therapeutics, Inc.
- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a...
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
October 29, 2024 12:55 ET
|
Cognition Therapeutics, Inc.
- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology - - ADAS-Cog 11 scores showed...
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
October 23, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE’ Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER’ trial in DLB ...
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
October 22, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
October 02, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative...
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
October 01, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...